Drug Profile
KiroCheck
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Kiromic
- Class Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Solid-tumours in USA
- 10 Aug 2016 Early research in Solid tumours in USA (unspecified route)